Taşpınar, M. Et Al. 2016. The role of MGMT, MLH1, MSH2, MSH6, PARP-1 and PMS-2 genes in cytotoxicity of Temozolomide of cell lines and tumour cells of primary patients with Glioblastoma. Personalised Medicine data – diagnosis–Decisions 2016 Congress , (Tuebingen, Germany), 3.

Taşpınar, M., Yüksek, V., Güner, E., Demirci, H., Tezcan, G., Uğur, H., ... Bekar, A.(2016). The role of MGMT, MLH1, MSH2, MSH6, PARP-1 and PMS-2 genes in cytotoxicity of Temozolomide of cell lines and tumour cells of primary patients with Glioblastoma . Personalised Medicine data – diagnosis–Decisions 2016 Congress (pp.3). Tuebingen, Germany

Taşpınar, Mehmet Et Al. "The role of MGMT, MLH1, MSH2, MSH6, PARP-1 and PMS-2 genes in cytotoxicity of Temozolomide of cell lines and tumour cells of primary patients with Glioblastoma," Personalised Medicine data – diagnosis–Decisions 2016 Congress, Tuebingen, Germany, 2016

Taşpınar, Mehmet Et Al. "The role of MGMT, MLH1, MSH2, MSH6, PARP-1 and PMS-2 genes in cytotoxicity of Temozolomide of cell lines and tumour cells of primary patients with Glioblastoma." Personalised Medicine data – diagnosis–Decisions 2016 Congress , Tuebingen, Germany, pp.3, 2016

Taşpınar, M. Et Al. (2016) . "The role of MGMT, MLH1, MSH2, MSH6, PARP-1 and PMS-2 genes in cytotoxicity of Temozolomide of cell lines and tumour cells of primary patients with Glioblastoma." Personalised Medicine data – diagnosis–Decisions 2016 Congress , Tuebingen, Germany, p.3.

@conferencepaper{conferencepaper, author={Mehmet Taşpınar Et Al. }, title={The role of MGMT, MLH1, MSH2, MSH6, PARP-1 and PMS-2 genes in cytotoxicity of Temozolomide of cell lines and tumour cells of primary patients with Glioblastoma}, congress name={Personalised Medicine data – diagnosis–Decisions 2016 Congress}, city={Tuebingen}, country={Germany}, year={2016}, pages={3} }